Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week High - What's Next?

Key Points

• Shares hit a new 52-week high of $14.43 in mid-day trading, with the stock trading around $14.4050 and a 50‑day/200‑day moving average of $14.33/$11.43.
• Multiple firms have downgraded the stock, leaving a consensus rating of Hold (three Buy, nine Hold, one Sell) and an average price target of $15.39, with several targets trimmed to $14.50.
• Amicus reported quarterly EPS of $0.10 (missing estimates of $0.13) while revenue of $185.21M roughly met expectations and rose 23.7% year‑over‑year.

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $14.43 and last traded at $14.4050, with a volume of 2213 shares. The stock had previously closed at $14.43.

Analyst Ratings Changes

A number of equities research analysts have issued reports on FOLD shares. Jefferies Financial Group reissued a "hold" rating and issued a $14.50 price target (down from $16.00) on shares of Amicus Therapeutics in a report on Thursday, January 22nd. Cantor Fitzgerald cut Amicus Therapeutics from an "overweight" rating to a "hold" rating and cut their target price for the stock from $21.00 to $14.50 in a research note on Friday, December 19th. Citigroup restated a "neutral" rating and set a $14.50 price target (down from $17.00) on shares of Amicus Therapeutics in a report on Monday, December 22nd. TD Cowen lowered Amicus Therapeutics from a "buy" rating to a "hold" rating and set a $14.50 price target for the company. in a research report on Monday, December 22nd. Finally, Needham & Company LLC cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, December 19th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Amicus Therapeutics has an average rating of "Hold" and a consensus price target of $15.39.

Amicus Therapeutics Stock Performance

The business has a fifty day simple moving average of $14.33 and a 200-day simple moving average of $11.43. The company has a quick ratio of 1.88, a current ratio of 2.84 and a debt-to-equity ratio of 1.43. The firm has a market cap of $4.52 billion, a P/E ratio of -179.94 and a beta of 0.43.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last announced its quarterly earnings data on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, missing analysts' consensus estimates of $0.13 by ($0.03). The business had revenue of $185.21 million during the quarter, compared to analysts' expectations of $185.00 million. Amicus Therapeutics had a positive return on equity of 4.15% and a negative net margin of 4.27%.Amicus Therapeutics's revenue for the quarter was up 23.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.09 EPS. On average, sell-side analysts predict that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 75,000 shares of the company's stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $14.31, for a total transaction of $1,073,250.00. Following the transaction, the chief executive officer owned 1,021,180 shares in the company, valued at approximately $14,613,085.80. This represents a 6.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.20% of the stock is owned by corporate insiders.

Institutional Trading of Amicus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Amicus Therapeutics by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 29,702,696 shares of the biopharmaceutical company's stock worth $422,966,000 after buying an additional 168,667 shares in the last quarter. William Blair Investment Management LLC grew its position in shares of Amicus Therapeutics by 7.6% during the third quarter. William Blair Investment Management LLC now owns 15,749,240 shares of the biopharmaceutical company's stock worth $124,104,000 after purchasing an additional 1,107,083 shares in the last quarter. HBK Investments L P purchased a new stake in shares of Amicus Therapeutics during the fourth quarter worth about $217,160,000. State Street Corp raised its stake in Amicus Therapeutics by 28.3% during the 4th quarter. State Street Corp now owns 14,833,314 shares of the biopharmaceutical company's stock valued at $211,226,000 after purchasing an additional 3,270,375 shares during the period. Finally, Vestal Point Capital LP raised its stake in Amicus Therapeutics by 178.4% during the 2nd quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company's stock valued at $68,187,000 after purchasing an additional 7,625,000 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics NASDAQ: FOLD is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company's lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.